Navigation Links
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
Date:8/4/2009

CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs." Allowed claims cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate. Palatin expects the patent will issue in the second half of 2009; the patent's 20-year term would expire in 2027.

"We are extremely pleased to be getting this patent coverage," said Palatin President and CEO Carl Spana. "PL-3994 and related compounds are first-in-class peptide mimetics with extended half-lives and favorable pharmacokinetic properties. These are the only drugs we are aware of that bind to NPRA and are suitable for subcutaneous administration, with the possibility of once-daily administration."

PL-3994 and the related family of cyclic compounds were discovered entirely in-house and are owned by Palatin. In addition to the allowed U.S. patent application, Palatin has applications pending in selected countries outside the United States and additional U.S. applications covering related compounds.

About PL-3994

Palatin has completed two clinical trials with PL-3994, a Phase 1 trial in healthy volunteers and a Phase 2a trial in patients with controlled hypertension. PL-3994 produced dose-related decreases in blood pressure, increases in plasma cGMP (cyclic guanosine monophosphate), a natural messenger nucleotide, and increases in urine volume and sodium excretion. There were no serious or severe adverse events.

PL-3994 incorporates a novel and proprietary amino acid mimetic developed by scien
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
2. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
3. Palatin Technologies Receives Notification Letter from NYSE Alternext US
4. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
5. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
6. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
10. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
11. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013  HealthSparq, a trusted provider of ... largest regional health plans, will debut a new ... (AHIP) Institute 2013 conference on June 13.  The ... how health insurance companies across the country are ... marketplace demands for increased healthcare transparency. ...
(Date:5/16/2013)... 2013 Scientists at the Center for Learning ... and the California -based biopharmaceutical company ... therapy for reversing memory decline in mice with Alzheimer,s ... cognitive improvement in advanced stage AD mice. The study ... cognitive decline for advanced stage AD mice, and is ...
(Date:5/16/2013)... 16, 2013 On average, developing a ... one billion dollars. Despite this investment, less than 10% ... high, is your clinical trial design optimally structured to ... outcomes? , Dr. Frederic Sax, Global Head of the ... use of data, information and technology in upfront clinical ...
(Date:5/16/2013)... , May 16, 2013 ... research report is available in its ... Cardiac Biomarkers for Acute Coronary Syndromes ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Acute Coronary Syndromes - APAC Analysis ...
Breaking Biology Technology:HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8
... 28 Thermo Fisher,Scientific Inc. (NYSE: TMO ), the world ... conferences: -- Thomas Weisel Partners Healthcare Conference on Friday, Sept. ... the Four Seasons Hotel, Boston, Mass., -- Bear Stearns 20th ... 2007, at 10:30 a.m. (EST) at The Grand Hyatt Hotel, New ...
... With 3.8 Million Patients Under ... ... Accretive to Medco Shareholders in ... 2008, FRANKLIN LAKES, N.J. and WAKEFIELD, Mass., Aug. 28 ,Medco Health Solutions, ...
... and Preclinical-Stage Compounds ... in Merck KGaA ... drug discovery and development company, announced today that,it will collaborate ... discover new applications for drug candidates. KineMed,s,proprietary pathway-based drug discovery ...
Cached Biology Technology:Thermo Fisher Scientific to Present at Investor Conferences 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 3Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 4Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 5Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 6Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 7KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 2
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
(Date:5/19/2013)... engineered a strain of electricity-producing bacteria that can grow ... carbon dioxide as its sole source of carbon. ... findings at the 113th General Meeting of the American ... of current production solely on hydrogen," says Amit Kumar, ... co-authors are part of the Lovley Lab Group at ...
(Date:5/19/2013)... University of California, Davis have engineered a strain of ... They report their findings today at the 113th ... "In this work, we used synthetic biology approaches to ... and light energy for growth) cyanobacterial metabolism for the ... the lead researcher on the study. He is ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2
... General Hospital (MGH) researchers discovered that the spleen ... that could regenerate the insulin-producing islets of the,pancreas. ... of the,same team now report that these potential ... be present only during the embryonic,development of mammals.,The ...
... bat, yet their evolutionary history is largely unknown because of ... their origins and divergence. , Now, a research team including ... a paper in the Jan. 28 issue of the journal ... fill in many of the gaps. , Springer coauthors the ...
... Contrary to the results of a recent U.S. study, ... infection and a potentially life-threatening form of high blood ... The Journal of Infectious Diseases, now available online. , ... detect human herpesvirus 8 (HHV-8), also known as the ...
Cached Biology News:Spleen may be source of versatile stem cells 2Spleen may be source of versatile stem cells 3Molecular biology fills gaps in knowledge of bat evolution 2Association of herpesvirus with lung disorder questioned 2
... SE flow cytometry system is the superior ... over 25 years, BD cell sorters have ... in leading university, pharmaceutical, and biotechnology research ... the research demands of today, we have ...
... allows real-time observations of cell cultures under ... 64 different strain parameters in addition to ... silicon strain chamber used by the ST-195 ... microscopy. ST-195 can be used with Nikon, ...
... RC DC protein assay reagents package is used ... reducing agents and detergents. The RC DC protein ... reagents sufficient for 500 standard assays: 250 ml ... 250 ml alkaline copper tartrate solution, 2 L ...
... Kit is designed for concentration and ... samples. Proteomics sample analysis is often ... impurities such as buffers, salts and ... interfere with electrophoretic separations or enzymatic ...
Biology Products: